| Literature DB >> 36187065 |
Mária Macháčková1, Matej Škrovina1,2, Mário Szikhart3, Lubomír Martínek1,4, Vladimír Benčurik1, Jiří Bartoš1, Michal Dosoudil1.
Abstract
Introduction: Over the last decades outcomes for rectal cancer surgery have improved, with increasing survival rates. Nevertheless, functional disorders are still frequent. Aim: To evaluate sexual and urinary outcomes of miniinvasive total mesorectal excision (TME). Material and methods: Between March 2016 and June 2018 patients with rectal cancer who underwent miniinvasive TME with a sphincter-saving procedure were enrolled. The questionnaires were completed before therapy, and 6, 12, and 24 months after stoma closure. We used the Female Sexual Function Index (FSFI), the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function questionnaire (IIEF).Entities:
Keywords: rectal resections; robotic surgery; urogenital dysfunction
Year: 2022 PMID: 36187065 PMCID: PMC9511913 DOI: 10.5114/wiitm.2022.116394
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.627
Figure 1Selection process
Clinical characteristics and characteristics of the tumour
| Parameter | Laparoscopy ( | Robotic (Da Vinci) ( | |
|---|---|---|---|
| Age [years] | 62.0 ±9.1 | 61.0 ±10.9 | 0.516 |
| Sex | 0.557 | ||
| Male | 24 (61.5) | 17 (62.9) | |
| Female | 15 (38.5) | 10 (37.0) | |
| BMI | 26.9 ±4.5 | 26.8 ±4.7 | 0.916 |
| ASA | 0.674 | ||
| ASA 1 | 0 (0) | 0 (0) | |
| ASA 2 | 24 (61.5) | 14 (51.8) | |
| ASA 3 | 14 (35.9) | 13 (48.2) | |
| ASA 4 | 1 (2.56) | 0 (0) | |
| Adjuvant therapy | 0.557 | ||
| Yes | 24 (61.5) | 17 (62.9) | |
| No | 15 (38.5) | 10 (37.0) | |
| Neoadjuvant therapy | 0.318 | ||
| Yes | 24 (61.5) | 19 (70.4) | |
| No | 15 (38.5) | 8 (29.6) | |
| Tumour distance from anal verge [mm] | 70.8 ±18.4 | 74.4 ±30.5 | 0.958 |
| TNM stage | 0.904 | ||
| pT1-2 | 15 (38.5) | 10 (37.0) | |
| pT3-4 | 24 (61.5) | 17 (63.0) | |
| Nodal stage | 0.827 | ||
| pN0 | 27 (69.2) | 18 (66.6) | |
| pN1-2 | 12 (30.8) | 9 (33.3) |
Values are mean (standard deviation).
Values are absolute number (percentage).
Independent-samples t-test.
Fisher’s exact test.
Mann-Whitney U test.
χ2
Operation data
| Parameter | Laparoscopy ( | Robotic (Da Vinci) ( | |
|---|---|---|---|
| Operative time [min] | 231.8 ±64.3 | 279.2 ±58.1 | 0.003 |
| Blood loss [ml] | 92.8 ±160.64 | 54.4 ±67.8 | 0.103 |
| Hospital stay [days] | 7.5 ±1.3 | 9.2 ±5.1 | 0.901 |
| Complications | 4 (10.3) | 4 (14.8) | 0.577 |
| Uroinfection | 1 | 0 | |
| Paralysis | 1 | 3 | |
| Intolerance of ileostomy | 2 | 0 | |
| Wound infection (minilaparotomy) | 0 | 1 | |
| Anastomotic leak | 2 (5.1) | 1 (3.7) | |
| 30-day mortality | 0 (0) | 0 (0) | |
| Ileostomy reversal – time from primary procedure [days] | 54.3 ±10.8 | 62.4 ±12.4 | 0.934 |
Values are mean (standard deviation).
Values are absolute number (percentage).
Independent-samples t-test.
Fisher’s exact test.
Mann-Whitney U test.
χ2.
IPSS score
| Variable | Laparoscopic TME ( | Robotic TME ( | |
|---|---|---|---|
| IPSS 1 | 3.8 ±3.6 | 5.8 ±4.0 | 0.128 |
| IPSS 2 | 6.1 ±6.3 | 8.6 ±5.3 | 0.090 |
| IPSS 3 | 5.8 ±6.0 | 7.7 ±4.9 | 0.125 |
| IPSS 4 | 5.1 ±5.6 | 7.5 ±4.9 | 0.085 |
Values are mean (standard deviation).
Mann-Whitney U test.
Figure 2International Prostatic Symptom Score
IIEF score
| IIEF | L-TME ( | R-TME ( | |
|---|---|---|---|
| IIEF 1 | 23.5 ±0.9 | 22.9 ±2.2 | 0.933 |
| IIEF 2 | 21.9 ±3.1 | 20.5 ±4.0 | 0.45 |
| IIEF 3 | 21.7 ±3.2 | 21.2 ±3.1 | 0.614 |
| IIEF 4 | 22.9 ±2.6 | 21.4 ±3.4 | 0.302 |
Values are mean (standard deviation).
Mann-Whitney U test.
Figure 3International Index of Erectile Function
FSFI score
| FSFI | L-TME ( | R-TME ( | |
|---|---|---|---|
| FSFI 1 | 31.1 ±2.9 | 32.1 ±3.4 | 0.421 |
| FSFI 2 | 28.2 ±5.4 | 31.9 ±3.5 | 0.175 |
| FSFI 3 | 28.9 ±5.0 | 32.1 ±3.2 | 0.175 |
| FSFI 4 | 30.8 ±6.0 | 32.9 ±2.9 | 0.33 |
Values are mean (standard deviation).
Mann-Whitney U test.
Figure 4Female Sexual Function Index